Pharmacology & Toxicology Flashcards
severe cutaneous adverse reaction allele
HLA-B *5801
type 1 diabetes allelee
HLA-B18
coeliac allele
HLA-DQ2
Multiple sclerosis allele
HLA-DR15
Trastuzumab
Trastuzumab (Herceptin) - monoclonal antibody that acts on the HER2/neu receptor
cardiotoxicity as SE - echo recommended prior to starting treatment
Brimonidine MoA
Brimonidine is an alpha-2-adrenergic agonist aiding in the management of open-angle glaucoma by decreasing aqueous humour production and increasing uveoscleral outflow.
BRIMonidine stops the aqueous humou fom BRIMMING ove/reaching the BRIM
Brinzolamide MoA
Brinzolamide is a carbonic anhydrase inhibitor that decreases aqueous humour production.
ZOLAMIDE = carbonic anhydrase inhibitor
Pilocarpine MoA
a muscarinic agonist which works by contracting the ciliary muscle, in turn opening the trabecular meshwork and thus increasing outflow of aqueous humour.
Used for open angle glaaucoma
Antibiotic class to be avoided in G6PD and what happens
Quinolones e.g. cipoflox
Heamolytic anaeamia with G6PD
managment of lithium toxicity
Management
mild-moderate toxicity may respond to volume resuscitation with normal saline
IV fluids with isotonic saline, until euvolemic, then typically twice maintenance rate
monitor serum sodium closely (every 4 hours with serial lithium concentrations) if there is a concern about lithium-induced nephrogenic diabetes insipidus
haemodialysis may be needed in severe toxicity
sodium bicarbonate is sometimes used but there is limited evidence to support this
by increasing the alkalinity of the urine it promotes lithium excretion
Carbon monoxide poisoning 1st line treatment
Carbon monoxide poisoning: 100% high-flow oxygen is the first-line treatment
Drug-induced impaired glucose tolerance
TASTINg Sugar( impared glucose tolerance)
Thiazides, Antiphychotics, Steroids, T cell in inhibitors(tacrolimus |&| cyclosporin), interferon alpha, nicotinic acid.
Sugar = impared glucose tolerance
buprenorphine MoA in opiod addiction
buprenorphine is a partial agonist of the mu-opioid receptor and an antagonist of the kappa-opioid. It binds to the mu-opioid receptors in the brain but only partially activates them. This partial activation is enough to alleviate cravings and withdrawal symptoms in individuals with opioid dependence. Furthermore, the binding of buprenorphine to the mu-opioid receptor is very strong, or ‘high affinity,’ meaning it can displace other opioids from these receptors and prevent them from exerting their effects. As a kappa-opioid receptor antagonist, buprenorphine may contribute to its ability to reduce symptoms of opioid withdrawal and potentially reduce depressive and dysphoric states.
characteristic of methanol toxicity
metabolic acidosis with a high anion gap; presents with visual disturbances that are characteristic of methanol toxicity
ethylene gycol toxicity management
fomepizole, an inhibitor of alcohol dehydrogenase, is now used first-line in preference to ethanol